No search results confirm NICE (UK cost gatekeeper) granting cardiovascular approval for Wegovy or adding 1M+ eligible patients; query premise unverified.
MHRA approved 'triple-strength' 7.2mg Wegovy injection for weight management in obesity on January 14, 2026; pending NICE review for NHS use and expected launch this year.1
Novo Nordisk states 7.2mg dose achieves 20.7% average weight loss vs. 2.4mg, with comparable side effects; aims to help patients not reaching goals on max current dose.1
Oral Wegovy pill (25mg daily semaglutide) launched in US January 2026 post-FDA approval; under MHRA review in UK with decision expected late 2026, pending NICE for NHS.23
Sources:
1. https://www.pharmacymagazine.co.uk/business-news/triple-strength-wegovy-injection-gets-mhra-approval
2. https://www.ukmeds.co.uk/blog/wegovy-pill-uk-guide
3. https://www.hl.co.uk/shares/share-research/novo-nordisk-announcement-oral-wegovy-pill-gains-fda-approval